Predictability of plasma concentration–time curves in humans using single-species allometric scaling of chimeric mice with humanized liver

References

• Arrowsmith J. (2011). Trial watch: phase II failures: 2008–2010. Nat Rev Drug Discov 10:328–9
   PubMed Web of Science ®Google Scholar
• Boxenbaum H, Ronfeld R. (1983). Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol 245:R768–75
   PubMed Web of Science ®Google Scholar
• Brown HS, Griffin M, Houston JB. (2007). Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Dispos 35:293–301
   PubMed Web of Science ®Google Scholar
• Davies NM, Watson MS. (1997). Clinical pharmacokinetics of sulindac. A dynamic old drug. Clin Pharmacokinet 32:437–59
   PubMed Web of Science ®Google Scholar
• Debruyne D, Hurault de Ligny B, Ryckelynck JP, et al. (1987). Clinical pharmacokinetics of ketoprofen after single intravenous administration as a bolus or infusion. Clin Pharmacokinet 12:214–21
   PubMed Web of Science ®Google Scholar
• Dedrick R, Bischoff KB, Zaharko DS. (1970). Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep 54:95–101
   PubMedGoogle Scholar
• Deguchi T, Watanabe N, Kurihara A, et al. (2011). Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach. Drug Metab Dispos 39:820–9
   PubMed Web of Science ®Google Scholar
• Di L, Feng B, Goosen TC, et al. (2013). A perspective on the prediction of drug pharmacokinetics and disposition in drug research and development. Drug Metab Dispos 41:1975–93
   PubMed Web of Science ®Google Scholar
• Díaz-García JM, Fos D. (1992). Residence time distribution of diazepam in the isolated perfused rat liver. Analysis with the axial dispersion model. Rev Esp Fisiol 48:221–9
   PubMedGoogle Scholar
• Dominic JA, Bourne DW, Tan TG, et al. (1981). The pharmacology of verapamil. III. Pharmacokinetics in normal subjects after intravenous drug administration. J Cardiovasc Pharmacol 3:25–38
   PubMed Web of Science ®Google Scholar
• FDA approval package (The source for this value is the PharmaPendium database from Elsevier) 8; 1990. Available at: https://www.pharmapendium.com/
   Google Scholar
• Gaudreault J, Varin F, Pollack GM. (1995). Pharmacokinetics and anticonvulsant effect of a new hypnotic, CL 284,846, in rats, Pharm Res 12:1592–7
   PubMed Web of Science ®Google Scholar
• Ghorab MK, Adeyeye MC. (2003). Enhanced bioavailability of process-induced fast-dissolving ibuprofen cogranulated with beta-cyclodextrin. J Pharm Sci 92:1690–7
   PubMed Web of Science ®Google Scholar
• Heizmann P, Eckert M, Ziegler WH. (1983). Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol 16 Suppl 1:43S–9S
   Google Scholar
• Helton DR, Osborne DW, Pierson SK, et al. (2000). Pharmacokinetic profiles in rats after intravenous, oral, or dermal administration of dapsone. Drug Metab Dispos 28:925–9
   PubMed Web of Science ®Google Scholar
• Hosea NA, Collard WT, Cole S, et al. (2009). Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49:513–33
   PubMed Web of Science ®Google Scholar
• Huh Y, Smith DE, Feng MR. (2011). Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs. Xenobiotica 41:972–87
   PubMed Web of Science ®Google Scholar
• Ings RM. (1990). Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica 20:1201–31
   PubMed Web of Science ®Google Scholar
• Izuwa Y, Kusaba J, Horiuchi M, et al. (2009). Comparative study of increased plasma quinidine concentration in rats with glycerol- and cisplatin-induced acute renal failure. Drug Metab Pharmacokinet 24:451–7
   PubMed Web of Science ®Google Scholar
• Jones HM, Barton HA, Lai Y, et al. (2012). Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos 40:1007–17
   PubMed Web of Science ®Google Scholar
• Josa M, Urizar JP, Rapado J, et al. (2001). Pharmacokinetic/pharmacodynamics modeling of antipyretic and anti-inflammatory effects of naproxen in the rat. J Pharmacol Exp Ther 297:198–205
   PubMed Web of Science ®Google Scholar
• Katoh M, Matsui T, Nakajima M, et al. (2004). Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metab Dispos 32:1402–10
   PubMed Web of Science ®Google Scholar
• Katoh M, Matsui T, Okumura H, et al. (2005). Expression of human phase II enzymes in chimeric mice with humanized liver. Drug Metab Dispos 33:1333–40
   PubMed Web of Science ®Google Scholar
• Kitamura S, Nitta K, Tayama Y, et al. (2008). Aldehyde oxidase-catalyzed metabolism of N1-methylnicotinamide in vivo and in vitro in chimeric mice with humanized liver. Drug Metab Dispos 36:1202–5
   PubMed Web of Science ®Google Scholar
• Kitamura S, Sugihara K. (2014). Current status of prediction of drug disposition and toxicity in humans using chimeric mice with humanized liver. Xenobiotica 44:123–34
   PubMed Web of Science ®Google Scholar
• Klotz U, Antonin KH, Bieck PR. (1976). Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. J Pharmacol Exp Ther 199:67–73
   PubMed Web of Science ®Google Scholar
• Klotz U, Avant GR, Hoyumpa A, et al. (1975). The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest 55:347–59
   PubMed Web of Science ®Google Scholar
• Kola I, Landis J. (2004). Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–15
   PubMed Web of Science ®Google Scholar
• Li C, Choi DH, Choi JS. (2012). Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine, J Pharmacokinet Pharmacodyn 39:99–108
   PubMed Web of Science ®Google Scholar
• Lombardo F, Waters NJ, Argikar UA, et al. (2013a). Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 1: volume of distribution at steady state. J Clin Pharmacol 53:167–77
   PubMed Web of Science ®Google Scholar
• Lombardo F, Waters NJ, Argikar UA, et al. (2013b). Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 2: clearance. J Clin Pharmacol 53:178–91
   PubMed Web of Science ®Google Scholar
• Marcellin P, de Bony F, Garret C, et al. (2001). Influence of cirrhosis on lamotrigine pharmacokinetics. Br J Clin Pharmacol 51:410–14
   PubMed Web of Science ®Google Scholar
• Martignoni M, Groothuis GM, de Kanter R. (2006). Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875–94
   PubMed Web of Science ®Google Scholar
• Martin W, Koselowske G, Töberich H, et al. (1990). Pharmacokinetics and absolute bioavailability of ibuprofen after oral administration of ibuprofen lysine in man. Biopharm Drug Dispos 11:265–78
   PubMed Web of Science ®Google Scholar
• Nakashima M, Uematsu T, Kanemaru M. (1992). Phase I study of AT-877 (Fasudil hydrochloride) in healthy subjects: single and multiple administration. Jpn Pharmacol Ther 20:S1559–85
   Google Scholar
• Naritomi Y, Terashita S, Kimura S, et al. (2001). Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29:1316–24
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Kajosaari LI, et al. (2005). Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 77:468–78
   PubMed Web of Science ®Google Scholar
• Nishimura M, Yoshitsugu H, Yokoi T, et al. (2005). Evaluation of mRNA expression of human drug-metabolizing enzymes and transporters in chimeric mouse with humanized liver. Xenobiotica 35:877–90
   PubMed Web of Science ®Google Scholar
• Nishimura T, Amano N, Kubo Y, et al. (2007). Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey. Drug Metab Dispos 35:1275–84
   PubMed Web of Science ®Google Scholar
• Obach RS, Baxter JG, Liston TE, et al. (1997). The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46–58
   PubMed Web of Science ®Google Scholar
• Obach RS, Lombardo F, Waters NJ. (2008). Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 36:1385–405
   PubMed Web of Science ®Google Scholar
• Ochs HR, Grube E, Greenblatt DJ, Arendt R. (1981). Intravenous quinidine in congestive cardiomyopathy. Eur J Clin Pharmacol 19:173–6
   PubMed Web of Science ®Google Scholar
• Ohkawa Y, Higashiyama K, Sugaya S, et al. (2001). Study on glutathionesulphonic acid as biodistribution promoter: concomitant use effect on verapamil hydrochloride and tegafur. Biol Pharm Bull 24:378–84
   PubMed Web of Science ®Google Scholar
• Oitate M, Nakayama S, Ito T, et al. (2012). Prediction of human plasma concentration-time profiles of monoclonal antibodies from monkey data by a species-invariant time method. Drug Metab Pharmacokinet 27:354–9
   PubMed Web of Science ®Google Scholar
• Okumura H, Katoh M, Sawada T, et al. (2007). Humanization of excretory pathway in chimeric mice with humanized liver. Toxicol Sci 97:533–8
   PubMed Web of Science ®Google Scholar
• Ono S, Hatanaka T, Miyazawa S, et al. (1996). Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica 26:1155–66
   PubMed Web of Science ®Google Scholar
• Perloff MD, von Moltke LL, Court MH, et al. (2000). Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. J Pharmacol Exp Ther 292:618–28
   PubMed Web of Science ®Google Scholar
• Pieters FA, Zuidema J. (1987). The absolute oral bioavailability of dapsone in dogs and humans. Int J Clin Pharmacol Ther Toxicol 25:396–400
   PubMed Web of Science ®Google Scholar
• Rosen AS, Fournié P, Darwish M, et al. (1999). Zaleplon pharmacokinetics and absolute bioavailability. Biopharm Drug Dispos 20:171–5
   PubMed Web of Science ®Google Scholar
• Sanoh S, Horiguchi A, Sugihara K, et al. (2012). Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver. Drug Metab Dispos 40:322–8
   PubMed Web of Science ®Google Scholar
• Sanoh S, Ohta S. (2014). Chimeric mice transplanted with human hepatocytes as a model for prediction of human drug metabolism and pharmacokinetics. Biopharm Drug Dispos 35:71–86
   PubMed Web of Science ®Google Scholar
• Satoh S, Hitomi A, Ikegaki I, et al. (2010). Amelioration of endothelial damage/dysfunction is a possible mechanism for the neuroprotective effects of Rho-kinase inhibitors against ischemic brain damage. Brain Res Bull 81:191–5
   PubMed Web of Science ®Google Scholar
• Sayama H, Komura H, Kogayu M. (2013). Application of hybrid approach based on empirical and physiological concept for predicting pharmacokinetics in humans – usefulness of exponent on prospective evaluation of predictability. Drug Metab Dispos 41:498–507
   PubMed Web of Science ®Google Scholar
• Shibayama T, Matsushita Y, Kurihara A, et al. (2007). Prediction of pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, in humans using animal data. Xenobiotica 37:91–102
   PubMed Web of Science ®Google Scholar
• Shim HJ, Kim YC, Lee JH, et al. (2005). Interspecies pharmacokinetic scaling of DA-8159, a new erectogenic, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics. Biopharm Drug Dispos 26:269–77
   PubMed Web of Science ®Google Scholar
• Tang H, Hussain A, Leal M, et al. (2007). Interspecies prediction of human drug clearance based on scaling data from one or two animal species. Drug Metab Dispos 35:1886–93
   PubMed Web of Science ®Google Scholar
• Tateno C, Miya F, Wake K, et al. (2013). Morphological and microarray analyses of human hepatocytes from xenogeneic host livers. Lab Invest 93:54–71
   PubMed Web of Science ®Google Scholar
• Tateno C, Yoshizane Y, Saito N, et al. (2004). Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165:901–12
   PubMed Web of Science ®Google Scholar
• Utoh R, Tateno C, Kataoka M, et al. (2010). Hepatic hyperplasia associated with discordant xenogeneic parenchymal-nonparenchymal interactions in human hepatocyte-repopulated mice. Am J Pathol 177:654–65
   PubMed Web of Science ®Google Scholar
• Van den Bergh A, Sinha V, Gilissen R, et al. (2011). Prediction of human oral plasma concentration-time profiles using preclinical data: comparative evaluation of prediction approaches in early pharmaceutical discovery. Clin Pharmacokinet 50:505–17
   PubMed Web of Science ®Google Scholar
• Ward KW, Smith BR. (2004). A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time. Drug Metab Dispos 32:612–19
   PubMed Web of Science ®Google Scholar
• Willis JV, Kendall MJ, Flinn RM, et al. (1979). The pharmacokinetics of diclofenac sodium following intravenous and oral administration. Eur J Clin Pharmacol 16:405–10
   PubMed Web of Science ®Google Scholar
• Zientek M, Jiang Y, Youdim K, Obach RS. (2010). In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. Drug Metab Dispos 38:1322–7
   PubMed Web of Science ®Google Scholar
• Zou P, Zheng N, Yu Y, et al. (2012). Preclinical pharmacokinetics of MI-219, a novel human double minute 2 (HDM2) inhibitor and prediction of human pharmacokinetics. J Pharm Pharm Sci 15:265–80
   PubMed Web of Science ®Google Scholar